TrialThe oncologist2026

Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers.

Omid Hamid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.